Study guide

4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging

Key Takeaways Explain This Topic AI

MAGIC skin staging is driven by the body surface area involved, with bullae or desquamation marking the most severe stage regardless of the percentage of body surface affected.

MAGIC liver staging uses bilirubin bands of 2-3, 3.1-6, 6.1-15, and greater than 15 mg/dL.

MAGIC adult lower-GI staging uses daily stool volume bands of 500-999, 1,000-1,500, and greater than 1,500 mL/day, but severe abdominal pain, ileus, or grossly bloody stool is stage 4 regardless of measured volume.

Histopathologic hallmarks on diagnostic tissue biopsy include dyskeratosis and apoptotic keratinocytes at the dermal-epidermal junction (skin), apoptotic enterocytes at the base of intestinal crypts with crypt drop-out (GI tract), and nonsuppurative destructive cholangitis with bile duct degeneration (liver).

Rash, diarrhea, and hyperbilirubinemia all have infectious and drug-related mimics, so organ staging is applied alongside an active differential rather than as a standalone diagnosis.

Last updated: September 2026

1. Clinical Organ Manifestations & Staging Criteria

Acute GVHD selectively damages three primary target organ systems: the Skin , the Gastrointestinal Tract , and the Liver . Standardized staging from Stage 0 to Stage 4 is determined objectively for each organ individually. +---------------------------------------------------------------------------------------------------+

  • | aGVHD TARGET ORGAN SPECTRUM |
  • | |
  • | [ 1. SKIN (~70-80% Cases) ] --------> Maculopapular Erythematous Rash, Pruritus, Pain, |
  • | Palmar/Plantar Erythema, Bullae, Desquamation (TEN-like) |
  • | |
  • | [ 2. GI TRACT (~50% Cases) ] -------> Upper: Anorexia, Early Satiety, Nausea, Vomiting |
  • | Lower: Copious Watery Green Diarrhea, Cramping, Hematochezia|
  • | |
  • | [ 3. LIVER (~30-40% Cases) ] -------> Cholestatic Jaundice, Scleral Icterus, Pruritus, |
  • | Direct Hyperbilirubinemia, Elevated Alk Phos & GGT |
  • +---------------------------------------------------------------------------------------------------+
  • 1. Cutaneous Acute GVHD

Clinical Presentation: The skin is the most common (>70%) and typically earliest presenting organ. Manifests as a fine, erythematous, blanching, maculopapular morbilliform eruption. It frequently begins around the periauricular areas, posterior neck, shoulders, palms of the hands, and soles of the feet before spreading centripetally to the trunk and extremities. Patients report intense pruritus, burning, or cutaneous tenderness.

Severe Manifestations: In severe cases, lesions coalesce into generalized erythroderma, followed by the formation of subepidermal fluid blisters (bullae), sheet-like epidermal peeling (desquamation), and a positive Nikolsky sign resembling Toxic Epidermal Necrolysis (TEN).

Differential Diagnosis: Drug hypersensitivity reaction (e.g., to beta-lactams, trimethoprim-sulfamethoxazole, vancomycin, voriconazole), viral exanthem (HHV-6, CMV, enterovirus), engraftment syndrome rash.

Diagnostic Biopsy: 3–4 mm skin punch biopsy reveals apoptotic keratinocytes (dyskeratosis / "satellite cell necrosis") at the dermal-epidermal junction, basal vacuolar degeneration, subepidermal clefting, and a sparse perivascular lymphocytic infiltrate.

2. Gastrointestinal Acute GVHD

Upper GI Manifestations: Characterized by profound anorexia, early satiety, food aversion, persistent nausea, and repeated non-bilious or bilious vomiting refractory to standard antiemetics. Patients often experience significant weight loss without lower GI symptoms.

Lower GI Manifestations: Characterized by copious, watery, green mucoid ("spinach-like") secretory diarrhea that continues unabated even when the patient is placed completely NPO (fasting). As mucosal sloughing progresses, stool becomes blood-tinged, progressing to frank gastrointestinal hemorrhage (hematochezia, melena), severe colicky abdominal cramping, tenesmus, and paralytic ileus.

Quantification Rule: Stool output must be collected in a calibrated commode/bedpan and measured strictly in mL/day (or mL/kg/day in pediatrics) over a rolling 24-hour period, excluding urine contamination.

Differential Diagnosis: Clostridioides difficile colitis, Cytomegalovirus (CMV) colitis, Adenovirus, Norovirus, Rotavirus, conditioning-induced mucosal sloughing, and Mycophenolate Mofetil (MMF)-induced enteropathy.

Diagnostic Endoscopy: Flexible sigmoidoscopy or esophagogastroduodenoscopy (EGD) with mucosal biopsy demonstrates apoptotic enterocytes in the crypt epithelium ("crypt cell apoptosis"), crypt drop-out, crypt abscesses, and extensive mucosal denudation.

3. Hepatic Acute GVHD

Clinical Presentation: Hepatic GVHD presents as painless, progressive cholestatic jaundice , scleral icterus, dark tea-colored urine, acholic (pale) stools, and pruritus. Hepatic GVHD often accompanies other organ involvement but can be difficult to distinguish from drug injury, infection, SOS, obstruction, or relapse; evaluate the full differential even when skin/GI findings are absent.

Laboratory profile: Acute hepatic GVHD is commonly cholestatic, with rising bilirubin and alkaline-phosphatase/GGT abnormalities, but hepatitic patterns can occur. No liver-test pattern is independently diagnostic, and synthetic dysfunction depends on severity and competing injury.

Differential Diagnosis: Sinusoidal Obstruction Syndrome (SOS/VOD), drug-induced liver injury (azoles, cyclosporine, tacrolimus, TPN cholestasis), viral hepatitis (CMV, HSV, VZV, HBV/HCV reactivation), sepsis-associated cholestasis, and biliary sludge/cholecystitis.

Biopsy: When tissue is needed and safe, the team chooses the route from bleeding risk and local expertise; a transjugular approach may reduce peritoneal bleeding risk. Compatible findings include bile-duct epithelial injury and portal inflammation, interpreted with infection, drug injury, SOS and other causes.

2. MAGIC Target-Organ Staging

Use the same consensus system when measuring serial response. Lower-GI stage may be assigned by adult volume, pediatric weight-based volume, or episode count; stage 4 is symptom-defined rather than a higher-volume bucket.

  • Stage Skin Liver: total bilirubin Adult lower GI Pediatric lower GI
  • 0 No GVHD rash <2.0 mg/dL <500 mL/day <10 mL/kg/day

1 Maculopapular rash <25% BSA 2.0–3.0 mg/dL 500–999 mL/day or 3–4 episodes/day 10–19.9 mL/kg/day or 4–6 episodes/day

2 Maculopapular rash 25–50% BSA 3.1–6.0 mg/dL 1,000–1,500 mL/day or 5–7 episodes/day 20–30 mL/kg/day or 7–10 episodes/day

3 Generalized erythroderma >50% BSA 6.1–15.0 mg/dL >1,500 mL/day or >7 episodes/day >30 mL/kg/day or >10 episodes/day

4 Generalized erythroderma >50% BSA with bullae or desquamation >5% BSA >15.0 mg/dL Severe abdominal pain with or without ileus, or grossly bloody stool, regardless of volume Same symptom-defined criteria

Upper GI: persistent nausea, vomiting or anorexia attributed to acute GVHD is recorded as present or absent; it is not assigned stages 1–4. Measure and document stool volume/episodes and bleeding consistently, and evaluate infection, medication injury and other mimics.

3. What a Biopsy Adds, and Why Treatment Rarely Waits for It

Acute GVHD is a clinical diagnosis supported by histology, and understanding what the biopsy actually resolves keeps its role in proportion.

Skin. A maculopapular eruption after conditioning has a broad differential that includes drug eruption, viral exanthem, engraftment syndrome, and chemotherapy toxicity. Biopsy shows apoptotic keratinocytes at the dermoepidermal junction with satellite lymphocytes, but the findings overlap with drug reaction, so the biopsy supports rather than settles the question.

Gastrointestinal. This is where biopsy changes management most often, because CMV colitis, other infectious colitis, and Clostridioides difficile can reproduce GVHD's presentation exactly, and treating one as the other is harmful in both directions. Endoscopic biopsy demonstrating crypt cell apoptosis and crypt dropout supports GVHD while simultaneously allowing viral and infectious testing on the same specimen.

Liver. Biopsy is often deferred because thrombocytopenia and coagulopathy make the procedure risky, and a transjugular approach may be used when tissue is essential.

The timing principle is consistent: obtain the specimen without delaying time-critical therapy. Severe or progressive disease is treated on clinical grounds while the biopsy is arranged, and the result then refines therapy rather than initiating it.